Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeeHive: GSK5764227 Monotherapy or in Combination With Dostarlimab in R/M HNSCC
NCT07408063Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Apr 2026
- Primary completion
- Jun 2030
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan in head and neck squamous cell carcinoma (HNSCC), sponsored by University Health Network. Started Apr 2026; status: recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07408063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07408063.